PR Newswire Clinical TrialsOriginal article
Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine
Data ReadoutpositiveensartinibPositive
AI Analysis
Summary
Betta's ensartinib demonstrated positive results in the ELEVATE study as postoperative adjuvant therapy for ALK-positive NSCLC, with findings published in The New England Journal of Medicine on July 8, 2026.
Clinical Trial Data
Outcome Details
ELEVATE study of ensartinib as postoperative adjuvant therapy published in The New England Journal of Medicine
Importance:7/10
Sentiment:
0.70
NSCLCALK-positiveadjuvant therapypublicationELEVATE study
Read the original article
Published by PR Newswire Clinical Trials on July 9, 2026 2:16 AM